Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808494 · ClinicalTrials.gov registry record
Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 242
- Enrollment target
NCT02808494: Completed study, sponsored by Illumina.
NCT02808494 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 242 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808494 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
Sample Collection Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-11-20 |
What the finished NCT02808494 record still lists
NCT02808494 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02808494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02808494 about?
NCT02808494 is a clinical study titled "Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers". Sample Collection Study
What is the current status of trial NCT02808494?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2016-03. Estimated completion is 2017-11-20.
Who is sponsoring clinical trial NCT02808494?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia